Loading the section…
The price of ADMA Biologics Inc (ADMA) on October 9, 2026 is 10.36 USD, +0.29% on the day. Over 52 weeks the stock traded between 7.21 USD and 20.46 USD; the price now sits 24% of the way up that range. Over the past year the price changed by -29.14%. The P/E ratio is 14.6, which is below the sector median (25.0). Market capitalization is 2.41 billion USD, rank 27 among 128 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 4 November 2026 · Earnings calendar
Change over the period shown (line colour): −28.80 %
ADMA Biologics Inc trades on Nasdaq under the ticker ADMA. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks ADMA has traded between 7.21 $ and 20.46 $. As of 9 October 2026 the price stood 23.78 % of the way from the 52-week low to the high.
Over one year ADMA shares fell 29.14 %; over six months they rose 6.80 %. Volatility over 90 days is 38.54 %. Dividends are not included: this is price change only, as of 9 October 2026.
ADMA trades at a price-to-earnings ratio of 14.6, below the sector median of 25.0. Price to sales is 4.7, above the sector median of 4.0. Price to book is 6.2, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 10.32 | 10.51 | 10.25 | 10.36 | 3M |
| 8 October 2026 | 10.09 | 10.45 | 10.03 | 10.33 | 4M |
| 7 October 2026 | 10.15 | 10.32 | 10.07 | 10.14 | 3M |
| 6 October 2026 | 10.20 | 10.35 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
No events for this security recently.
ADMA Biologics Inc (ADMA) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 509.9m $, net income was 165.4m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17, RAMSEY, NJ, 07446, US
ADMA Biologics Inc reported revenue of 510M $ and net income of 165M $ over the last four quarters. Net margin is 32.43 %. Revenue changed by +10.99 % year over year. Earnings per share are 0.68 $. Market capitalisation is 2.4B $.
ADMA has a return on equity of 42.36 %, above the sector median of −41.68 %. Return on assets is 24.86 %, above the sector median of −32.11 %. Operating margin is 42.14 %, above the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 110.42 | +0.53 % | 253M |
| BIIBBiogen Inc. | 225.71 | +3.33 % | 227M |
| KODKodiak Sciences Inc | 99.87 | +5.95 % | 219M |
| 9.98 |
| 10.18 |
| 2M |
| 5 October 2026 | 9.63 | 10.19 | 9.62 | 10.11 | 4M |
| 2 October 2026 | 10.02 | 10.29 | 9.68 | 9.72 | 3M |
| 1 October 2026 | 10.07 | 10.26 | 9.91 | 9.93 | 4M |
| 30 September 2026 | 9.98 | 10.14 | 9.80 | 10.03 | 3M |
| 29 September 2026 | 10.04 | 10.19 | 9.89 | 9.96 | 3M |
| 28 September 2026 | 9.38 | 10.17 | 9.25 | 10.12 | 4M |
| 25 September 2026 | 9.55 | 9.63 | 9.23 | 9.38 | 4M |
| 24 September 2026 | 9.67 | 9.83 | 9.37 | 9.52 | 3M |
| 23 September 2026 | 9.81 | 9.84 | 9.43 | 9.70 | 3M |
| 22 September 2026 | 9.54 | 9.84 | 9.45 | 9.81 | 3M |
| 21 September 2026 | 9.19 | 9.54 | 9.10 | 9.51 | 3M |
| 18 September 2026 | 8.92 | 9.13 | 8.81 | 9.11 | 11M |
| 17 September 2026 | 9.00 | 9.05 | 8.88 | 8.95 | 2M |
| 16 September 2026 | 8.59 | 8.98 | 8.54 | 8.90 | 3M |
| 15 September 2026 | 9.08 | 9.13 | 8.55 | 8.61 | 4M |
| 14 September 2026 | 9.34 | 9.38 | 9.07 | 9.14 | 3M |